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Abstract
Background: Mortality among TB/HIV co-infected patients is still high particularly in developing countries. This study
aimed to determine the predictors of death in TB/HIV co-infected patients during TB treatment.
Methods: We reviewed medical records at the time of TB diagnosis and subsequent follow-up of all newly registered
TB patients with HIV co-infection at TB clinics in the Institute of Respiratory Medicine and three public hospitals in the
Klang Valley between January 2010 and September 2010. We reviewed these medical records again twelve months
after their initial diagnosis to determine treatment outcomes and survival. We analysed using Kaplan-Meier and
conducted multivariate Cox proportional hazards analysis to identify predictors of death during TB treatment in
TB/HIV co-infected patients.
Results: Of the 227 patients studied, 53 (23.3%) had died at the end of the study with 40% of deaths within two
months of TB diagnosis. Survival at 2, 6 and 12 months after initiating TB treatment were 90.7%, 82.8% and 78.8%
respectively. After adjusting for other factors, death in TB/HIV co-infected patients was associated with being Malay
(aHR 4.48; 95%CI 1.73-11.64), CD4 T-lymphocytes count < 200 cells/µl (aHR 3.89; 95% CI 1.20-12.63), three or
more opportunistic infections (aHR 3.61; 95% CI 1.04-12.55), not receiving antiretroviral therapy (aHR 3.21; 95% CI
1.76-5.85) and increase per 103 total white blood cell count per microliter (aHR 1.12; 95% CI 1.05-1.20)
Conclusion: TB/HIV co-infected patients had a high case fatality rate during TB treatment. Initiation of antiretroviral
therapy in these patients can improve survival by restoring immune function and preventing opportunistic infections.
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Introduction
Tuberculosis and human immunodeficiency virus (TB/HIV)
co-infection is an important global public health problem. TB is
the most common opportunistic infection and the leading cause
of death in HIV-infected patients [1]. Globally, there were an
estimated 8.7 million incident cases of TB in 2011 with 13%
were co-infected with HIV. There were almost a million deaths
among HIV-negative TB patients with an additional 0.43 million
deaths reported among HIV-positive TB patients [2].
Malaysia is categorized by the World Health Organization
(WHO) as an intermediate TB burden country [3]. As in other
developed and industrialized countries, the TB problem in
Malaysia had declined significantly between 1970 and 1980.
Factors that have contributed to the reduction in TB incidence
include improvements in socioeconomic status, better
ventilation of homes and work sites; and an improved health
system. However, from early 1995, the incidence of
tuberculosis has slowly increased from an incidence rate of 58
per 100,000 in 1995 to 72 per 100,000 in 2011. Several factors
were responsible for the increasing TB incidence including the
HIV infection, influx of immigrants from endemic neighbouring
countries, increased in urban migration and drug abuse. The
HIV epidemic reinforces the need to focus on the identification
and cure of infectious TB patients [4].
The present study reports on the survival of a cohort of HIV-
positive tuberculosis patients registered in 2010 in the central
region of Malaysia. In Malaysia, there is still a gap in
knowledge in the understanding of TB/HIV co-infection
particularly on the survival and predictors of death in TB-HIV
co-infected patients. Most of the studies on TB/HIV survival
were conducted in African countries. Some studies have been
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published recently in neighbouring countries such as Thailand
and Vietnam [5–8]. There are only a few articles regarding
characteristics of TB/HIV co-infected patients in selected states
in Malaysia [9,10]; but none has reported on the survival and
predictors of death. The aim of this study was to evaluate the
survival time and predictors of death in Malaysian HIV-infected
tuberculosis patients.
Study Population and Methods
Patients who were registered for TB treatment between
January 2010 and September 2010; and who were
documented to have a concomitant HIV infection in the Institute
of Respiratory Medicine and three public hospitals in Selangor
(Kajang Hospital, Klang Hospital and Sungai Buloh Hospital)
between January 2010 and September 2010 were included in
the study.
In Malaysia, all TB patients are routinely screened for HIV,
based on the guidelines of the Ministry of Health in 2002 [11].
The HIV test was done at the time of TB diagnosis. HIV
enzyme-linked immunosorbent assay (ELISA) test results for
these patients were traced and those who had positive results
included in the study.
Inpatient and outpatient medical records as well as TB
Information System (TBIS) documents were reviewed to obtain
all the dependent and independent variables including
information on socio-demographic data, lifestyle factors, clinical
characteristics and laboratory profiles. The information
gathered was used to complete a standard data collection
form. To ensure confidentiality, each case was assigned a
study identification number that was included on all records as
personal identifiers.
Patients who were transferred out to other treatment centres
or had their initial TB diagnosis changed to other diagnosis by
the attending physician were excluded from the study. Then the
patients’ survival status and their survival times were
determined. For this purpose, patients were followed up until
30th September 2011.
There were also patients who had either defaulted treatment
or were lost to follow-up. In these patients, their mortality or
survival status was obtained by contacting the patients or
relatives through the phone number or address as recorded in
their medical records. We confirmed their survival status
through the National Registration Department. We further
checked their names against the Electoral Register of 2011 to
confirm their mortality status.
We defined the survival time as the time from TB diagnosis
to death, which is the interval between the date on which TB
was diagnosed and the date of death. Patients were censored
at the date of the last visit if they were lost to follow-up. All
patients who survived were censored from the study on 30
September 2011. We classified any death that occurred during
TB treatment as TB death, consistent with WHO guidelines
[12]. We also analysed the predictors of death in TB/HIV co-
infected patients. Sociodemographic characteristics that were
investigated included age, gender, ethnicity, nationality,
employment status, marital status and incarceration. Lifestyle
characteristics were: smoking status, alcohol intake, mode of
HIV transmission and body weight. Clinical characteristics
were: types of TB, status of TB diagnosis, TB symptoms at
presentation (fever, cough with sputum, night sweat), changed
in TB treatment, co-morbidity with diabetes mellitus, number of
opportunistic infections and status of antiretroviral therapy.
Laboratory characteristics were: baseline haemoglobin level,
total white blood cell, serum albumin, CD4 counts, HbsAg,
toxoplasma serology and anti-HCV serology.
Statistical analysis
We entered the data and analysed it using SPSS 17.0. All
continuous variables were described using means and
standard deviations while categorical variables were described
using counts and proportions (%). The Kaplan-Meier technique
was employed to plot the survival graph. We used Cox
proportional hazard regression analysis to identify independent
predictors of death. We checked for interaction and adjusted
for confounding. We selected the final model based on the
principle of parsimony and best fit using the Hosmer-
Lemeshow approach of using -2 log likelihood ratios. We
presented the results in the form of hazard ratios (HR) and
95% confidence intervals (CI). The level of significance was set
at 0.05.
Ethics
Ethical clearance was obtained from the Medical Ethics
Committee of University of Malaya (MEC Ref No. 776.11) and
from the Medical Review and Ethics Committee (MREC),
Ministry of Health Malaysia with the reference number
NMRR-10-1201-6599. The requirement to obtain informed
written consent from each individual was waived by the Medical
Review and Ethics Committee, Ministry of Health Malaysia as
the study was limited to review of existing medical records.
Results
Socio-demographic characteristics
A total of 2262 tuberculosis patients were registered between
1st January 2010 and 30th September 2010 in Hospital Sungai
Buloh, Hospital Kajang, Hospital Tuanku Ampuan Rahimah,
Klang; and Institute of Respiratory Medicine, Kuala Lumpur.
Among them, 267 patients (11.8%) were co-infected with HIV.
Of these 267, 32 (12.0%) had been transferred out to other
treatment centres and 8 (3.0%) had their diagnoses changed
because they were later found to have a different diagnosis.
This meant that a total of 40 patients had to be excluded from
the study, leaving 227 patients eligible for analysis.
The mean age of TB/HIV co-infected patients were 39.1 (SD
8.6) years old and ranged from 16 to 62 years. The peak age
group was 35 to 54 years old (62.1%). Male to female ratio was
7:1. Ethnic Malays constituted the highest proportion (48.5%)
of patients followed by Chinese (16.3%), Indians (16.3%) and
Others (18.9%). The majority of them were Malaysians (n=185,
81.5%) while non-Malaysians who originated from Myanmar,
Indonesia, Nepal and Thailand constituted 18.5% (n=42). More
than half the patients were unemployed (57.3%, n=130). The
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majority of TB/HIV co-infected patients were single or divorced
(67.0%, n=152).
Survival curve and predictors of death
To determine the survival of TB/HIV co-infected patients
during TB treatment, the survival status of all patients (n =
227), including those who were still on TB treatment were
assessed at the end of the study period. Patients whose
treatment were interrupted for two months or more were
classified as ‘treatment defaulted’. At the end of the study
period, 25.6% (n=56) had defaulted treatment. To verify the
patient’s status, patients data were linked to the National
Registration Department database. Patients who died during
treatment default were reclassified as having died instead of
having defaulted treatment. In total, seven (7) patients who
were originally classified as defaulters were later reclassified as
having died, giving the total number of deaths during TB
treatment to be 53 (23.3%).
The mean follow-up duration was 14.3 months (SD 6.3)
months and the median was 15.9 (IQR 5.8) months. Survival at
2, 6 and 12 months after initiating TB treatment were 90.7%
(95% CI: 90.3-91.1), 82.8% (95% CI: 82.6-83.1) and 78.8%
(95% CI: 78.3-79.3) respectively. The survival curve becomes
much flatter after 6-months of TB treatment (Figure 1).
Table 1 displays the frequency and univariate Cox
regression analyses of sociodemographic and lifestyle
characteristics in TB/HIV co-infected patients. Table 2 displays
the frequency and univariate Cox regression analyses of
clinical and laboratory characteristics in TB/HIV co-infected
patients. The log rank p value less than 0.25 was set as cut off
value to choose predictors for entry into multiple Cox
proportional hazards regression analysis. The cut off of p less
than 0.25 was chosen in order not to miss significant predictors
which may have been confounded during univariate analysis.
The outcome is a single outcome variable with two categories
(alive or dead). There were seventeen predictors with a log
Figure 1.  Kaplan-Meier survival curve of TB/HIV co-
infected patients (n=227).  
doi: 10.1371/journal.pone.0073250.g001
rank p-value of less than 0.25 - age group, marital status,
ethnicity, employment status, incarceration, body weight, cough
with sputum at diagnosis, night sweats, co-morbidity with
diabetes mellitus, number of opportunistic infections,
antiretroviral therapy (ART), haemoglobin level, serum albumin
level, total white blood cell count, toxoplasma serology test,
anti-HCV serology and CD4 T-lymphocytes counts. During the
multivariate analysis analysis using Cox proportional hazards
regression model; ethnicity, number of opportunistic infections,
anti-retroviral therapy, total white blood cell count (WBC) and
CD4 T-lymphocytes were found to be associated with death in
TB/HIV co-infected patients (Table 3).
Ethnicity is the strongest risk factor for death in this study.
The risk of dying in Malays is almost five times higher than
ethnic group classified as ‘Others’ (HR: 4.48; 95%CI:
1.73-11.64).
Low CD4 T-lymphocytes count is the strongest clinical
predictor of death in TB/HIV co-infected patients. Patients with
CD4 T-lymphocytes count less than 200 cells/µl had almost
four times higher risk of death compared to CD4 T-lymphocytes
count more than 200 cells/µl (HR 3.89; 95% CI: 1.20-12.63).
Patients with three or more opportunistic infections had 3.61
times higher risk of death than patients who do not have any
opportunistic infection (HR: 3.61; 95%CI: 1.04-12.55). The risk
of death in patients who were not on antiretroviral therapy was
3.21 times compared to patients on antiretroviral therapy (HR:
3.21; 95%CI: 1.76-5.85). For every 103 cells per microliter unit
increase in total white blood cell, the risk of death increased by
12% (HR: 1.12; 95%CI: 1.05-1.20).
Discussion
TB is a common opportunistic infection and cause of death in
HIV-infected patients in many parts of the world, particularly in
developing countries. Results in our study have estimated the
prevalence of TB/HIV in Klang Valley is 11.0% which is slightly
higher than the national prevalence of HIV-infected patients
among tested TB patients in Malaysia (7.2%) in 2010 [2]. HIV
prevalence in TB patients in Asia ranged from 0.9% to 38% in
2010 [2]. TB/HIV co-infection is still relatively low in Malaysia
compared to other countries in Asia.
Data from the National TB Control Programme showed that
the rate of TB death in Malaysia in 2011 was 8.0% of the total
notified TB cases in that year [13]. Our study denotes that HIV
increases the risk of death in our patient cohort. HIV infection
as a predictor of death in TB patients has been established in
many previous studies [14–19]. In this study, death during TB
treatment occurred in 53 (23.3%) of TB/HIV co-infected
patients with 40% of deaths occurring within two months of TB
diagnosis. This finding is similar to case fatality rates during TB
treatment that was reported in previous studies in Thailand,
which was 29% [5] and Vietnam (26%) [8].
Ethnicity is the only social risk factor for survival in this study.
Malays had almost five times higher risk of death than the
ethnic group classified as ‘Others’ (HR: 4.48; 95%CI:
1.73-11.64) even after adjusting for potential confounders
including employment status, body weight and serum albumin
level in multivariate analysis. This warrants further research as
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reasons for this are not very clear. Future research might
investigate the ethnic differences in relation to treatment
adherence and access to care.
The finding that every 103 increase in total white blood cell
per microliter (HR: 1.12; 95%CI: 1.05-1.20) is associated with
higher mortality in HIV-infected TB patients finding is novel. We
have not found any studies in the literature that present a
similar association. Most previous studies have focused on T
lymphocyte subsets, particularly CD4+, and generally reported
depressed CD4+ T cells in peripheral blood of TB patient. In
this study, the total white blood cell results were that
Table 1. Frequency and univariate Cox regression analyses
of socio-demographic and lifestyle characteristics in 227
TB/HIV co-infected patients.
Variables N (%) HR (95%CI)  p-value
Age group, year     
≤ 34 73 (32.2) 1   
35-54 141 (62.1) 1.70 (0.89, 3.26)  0.108
≥ 55 13 (5.7) 1.48 (0.42, 5.24)  0.545
Age (mean (SD)) 39.1 + 8.6 years   
Gender     
Male 200 (88.1) 1.01 (0.43, 2.35)  0.992
Female 27 (11.9) 1   
Ethnicity     
Malay 110 (48.5) 2.90 (1.14,7.41)  0.026
Chinese 37 (16.3) 1.17 (0.34,4.03)  0.807
Indian 37 (16.3) 1.89 (0.62,5.77)  0.266
Others 43 (18.9) 1   
Nationality     
Malaysian 185 (81.5) 1.75 (0.40, 7.76)  0.280
Non- Malaysian 42 (18.5) 1   
Employment status     
Employed 97 (42.7) 1   
Unemployed 130 (57.3) 0.39 (0.21, 0.73)  0.003
Marital status     
Single/divorced 152 (67.0) 1.78 (0.94, 3.39)  0.079
Married 75 (33.0) 1   
Incarcerationa     
Yes 21 (18.5) 0.39 (0.20, 0.78)  0.008
No 206 (81.5) 1   
Smoking status     
Smoker 168 (74.0) 0.72 (0.37,1.39)  0.325
Non-smoker 59 (26.0) 1   
Alcohol intake     
No 173 (76.2) 0.91 (0.46,1.86)  0.777
Yes 54 (23.8) 1   
Mode of HIV transmission     
IVb drug users 127 (55.9) 1.08 (0.33, 3.48)  0.902
Sexual 89 (39.6) 0.35 (0.10,1.27)  0.311
Othersc 11 (4.5) 1   
Body weight (Mean (SD)) 49.7 (±9.0)kg 0.97 (0.94-1.00)  0.059
aIncarceration: Prisoners/Drug Rehabilitation Centre inmates at the time of TB
diagnosis.
bIV:intravenous
cOthers: Blood transfusion (n=1) and Unknown (n=10)
Table 2. Frequency and univariate Cox regression analyses
of clinical and laboratory characteristics in 227 TB/HIV co-
infected patients.
Variables N (%) HR (95%CI) p-value
Types of TB    
Smear positive PTB 92 (40.5) 1.02 (0.53, 1.97) 0.944
Smear negative PTB 71 (31.3) 0.94 (0.46, 1.90) 0.857
Extrapulmonary TB 64 (28.2) 1  
Status of TB diagnosis    
Newly diagnosed TB 161 (70.9) 0.85 (0.48,1.51) 0.575
Ever had TB before 66 (29.1) 1  
Fever    
Yes 170 (74.9) 1.04 (0.56-1.94) 0.904
No 57 (25.1) 1  
Cough with sputum    
Yes 110 (48.5) 1.63 (0.94, 2.81) 0.081
No 117 (51.5) 1  
Night sweats    
Yes 98 (43.2) 0.64 (0.36, 1.13) 0.125
No 129 (56.8) 1  
Changed in TB treatmenta    
Yes 37 (16.4) 0.99 (0.48, 2.03) 0.982
No 190 (83.7) 1  
Diabetes Mellitus    
Yes 6 (2.6) 0.44 (0.14, 1.40) 0.165
No 221 (97.4) 1  
Number of OIb    
No OI 119 (52.4) 1  
One OI 79 (34.8) 1.86 (1.02, 3.39) 0.430
Two OIs 23 (10.1) 2.02 (0.85,4.78) 0.110
Three or more OIs 6 (2.6) 3.72 (1.10,12.52) 0.340
Anti-retroviral therapy    
Yes 140 (61.7) 1  
No 87 (38.3) 2.50 (1.45, 4.31) 0.001
Hemoglobin level    
< 12 g/dL 178 (78.4) 1.60 (0.75,3.40) 0.221
≥ 12 g/dL 49 (21.6) 1  
Total White Blood Cells    
(Mean (SD)) 6.3 (± 3.3) 103/µl 1.12 (1.05-1.18) < 0.001
Serum albumin    
(Mean (SD)) 26.5 (± 7.5) g/L 0.90 (0.86, 0.94) < 0.001
CD4 count    
Not available 168 (74.0) 3.95 (0.94, 16.53) 0.060
< 200 cells/µl 39 (17.2) 3.90 (1.21,12.54) 0.023
≥ 200 cells/µl  1  
HbsAg    
Reactive 15 (6.6) 0.82 (0.26-2.63) 0.737
Non-reactive/unknown 212 (93.4) 1  
Toxoplasma serology test    
Reactive 51 (22.5) 1.77 (0.99, 3.15) 0.053
Non-reactive/unknown 176 (77.5) 1  
Anti-HCV serology    
Reactive 127 (55.9) 1.73 (0.97, 3.08) 0.062
Non-reactive/unknown 89 (39.2) 1  
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documented at the time of TB diagnosis (pre-TB treatment).
This finding may reflect that the risk of dying is increased with
the severity of infection at TB diagnosis.
The immune responses against HIV-infected tuberculosis
have not been fully clarified. Generally, infection will cause
white blood cells to be elevated. The major types of white blood
cells; neutrophils, lymphocytes, monocytes, eosinophils and
basophils play a different role in the immune system with a
different disease-fighting activity. In active TB disease,
neutrophils and monocytes are the main components of white
blood cell that response to mycobacterial infection [20]. A
recent study by Berry et al supported that neutrophils play a
role in the pathogenesis of TB which resulted from over-
activation by IFN-gamma and type I IFNs [21]. A study in South
Africa found that patients at TB diagnosis had a high absolute
neutrophil and monocyte counts which depleted during
treatment but low lymphocyte subset counts which increased
with TB treatment [22]. However, in patients who were co-
infected with HIV, HIV viruses will attack lymphocytes and
causing further depletion of CD4+ T cells. There is conflicting
evidence on the effect of Mycobacterium tuberculosis (MTB) on
HIV replication but several studies shown that MTB infection
Table 2 (continued).
aChanged in treatment: change from the initial TB regime (HRZ) to another due to
side effects of treatment or adverse reaction.
bOI: Opportunistic infection
Table 3. Final Cox regression model predictors of death in
TB/HIV co-infected patients.
Characteristics Adjusted HRa   95%CI p-value
Ethnicity    
Malay 4.48 1.73-11.64 0.002
Chinese 1.78 0.51-6.25 0.370
Indian 2.40 0.76-7.56 0.134
Others 1.00 -  
CD4 T-lymphocytes count    
Not available 2.21 0.50-9.81 0.299
< 200 cells/µl 3.89 1.20-12.63 0.024
≥ 200 cells/µl 1.00 -  
Number of Opportunistic infections (OI)    
No OI 1.00 -  
One OI 2.68 1.40-5.13 0.003
Two OIs 3.32 1.33-8.29 0.010
Three or more OIs 3.61 1.04-12.55 0.044
Anti-retroviral therapy    
Yes 1.00 -  
No 3.21 1.76-5.85* <0.001
Total White Blood Cells 1.12 1.05-1.20* 0.001
HR: Hazards Ratio, CI: Confidence Interval. aAdjusted for age group, marital
status, employment status, incarceration, body weight, cough with sputum at
diagnosis, night sweats, co-morbidity with diabetes mellitus, haemoglobin level,
serum albumin level, toxoplasma serology test and anti-HCV serology.
may increase HIV replication and worsen the patient’s immune
status [23].
Another factor that is independently associated with
decreased survival in this study is the number of opportunistic
infections. Patients with three or more types of opportunistic
infections have 3.61 times higher risk of death than patients
who do not have any opportunistic infection (HR: 3.61; 95% CI:
1.04-12.55). The finding that opportunistic infection is
associated with death were consistent with other studies in this
area [24–28]. Although these studies demonstrated a positive
association between opportunistic infections and death in
TB/HIV co-infected patients, they did not examine the
relationship between the number of opportunistic infections and
risk of death. To our knowledge, this is the first study to report
that the number of opportunistic infections is associated with
death in TB/HIV co-infection. TB is known to be the most
common opportunistic infections in HIV patients. A study by
Wong et al in South Africa who investigated the cause of death
on antiretroviral therapy by needle biopsy found that TB was
the main cause of death regardless of antiretroviral status (pre-
ART, early-ART or late-ART); with disseminated TB
responsible for 87% of deaths in the first three months of ART
[29].
In addition to concurrent opportunistic infections, not
receiving antiretrovirals (HR: 3.21; 95% CI: 1.76-5.85) is also
associated with death in TB/HIV co-infected patients. This
study demonstrated that ART can improve both the TB
treatment outcome and also survival. The mean survival time of
patients on ART is 19.0 months (95% CI: 18.1-20.0) and the
mean survival time of patients who were not on ART is 15.1
months (95% CI: 13.2-17.0). The survival probability at 12
months for patients on ART is 86.3% compared to 66.7% in
patients who were not on ART. This finding shows that HIV-
infected TB patients treated with ART had almost 23% better
survival compared with those who were not treated with ART.
The benefit of ART in reducing the death rates of TB/HIV co-
infected patients have been well documented in other studies
[5,7,30–32]. The widespread use of antiretroviral therapy since
1996 has markedly improved the survival of HIV-infected
patients both in developing and developed countries by
reducing the number of deaths from many opportunistic
infections. In TB/HIV co-infected patients, to introduce
antiretroviral therapy is not an easy decision because of
concerns about immune reconstitution inflammatory syndrome
(IRIS). However, Velasco et al proved that HIV-associated TB
patients will have better survival if HAART and TB treatment
were started concurrently (aHR 0.37, 95% CI 0.17–0.66) [33].
There have been clinical trials that show timely initiation of
antiretroviral therapy in TB/HIV co-infected patients save lives
particularly those with low CD4 [34–37]. A recent clinical trial by
Abdool Karim et al., comparing the outcomes in early versus
late ART concluded that in severely immune-compromised
patients with CD4 counts less than 50/mm3, ART should be
started as soon as possible after the start of TB treatment [38].
Although earlier ART is associated with a higher risk of IRIS,
but the finding that it is also associated with two thirds lower
risk of death than later ART is far more important (incidence
rate ratio, 4.7). However, for those with CD4 counts higher than
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50/mm3, they recommended that the initiation of ART be
deferred until the first four weeks of continuation phase of TB
treatment in order to reduce the risk of IRIS [38].
This study adds to the literature that low CD4 T-lymphocytes
are associated with higher risk of death in TB/HIV co-infected
patients during TB treatment. In our study, patients with CD4 T-
lymphocytes count lower than 200 cells/µl had almost four
times higher risk of death compared to those with CD4 T-
lymphocytes count more than 200 cells/µl (HR 3.89; 95% CI:
1.20-12.63). This finding is well established in other previous
studies [5,24,25,30,31,33,39,40]. The mean survival time of
patients with CD4 < 200 cells/µl is 17.0 months (95% CI:
15.8-18.2) which is lower than the mean survival time for
patients with CD4 > 200 cells/µl (20.0 months; 95% CI:
18.7-21.1). The mean survival time for patients whose CD4
counts are not available is 16.1 months (95% CI: 12.5-19.8)
which is similar to those with CD4 < 200 cells/µl; suggesting
that this group of patients might have had lower CD4 counts as
well. Even though opportunistic infections usually occur at less
than 200CD4+ cells/µl, pulmonary TB is commonly thought to
occur at a higher concentration [41].
This study is limited by its observational study design. In this
study, some of the predictors that had been related to observed
survival in other studies of TB/HIV co-infected patients such as
Directly Observed Treatment (DOT) supervision, Tuberculin
skin testing (TST), co-trimoxazole preventive therapy; and
complications regarding treatment were not assessed. It would
also interesting to know the differential for the WBC particularly
the absolute neutrophil count. However, these predictors were
excluded from the analysis because data related to these
predictors were incomplete or unavailable in many patients’
record.
This is the first study to explore the risk of death during TB
treatment in TB/HIV co-infected patients in Malaysia. A better
understanding of the predictors of death among Malaysians
could provide opportunities for policy makers to estimate the
burden of HIV infection among active TB cases in Malaysia;
thus enabling informed decisions on priorities. The results of
this study will also help to engage policy makers, researchers
and communities in working together to generate the
knowledge that is needed for better care for TB/HIV co-infected
patients in Malaysia; as well as to promote further research in
this area.
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